Skip to main content
Figure 3 | Respiratory Research

Figure 3

From: Thiazolidinediones inhibit airway smooth muscle release of the chemokine CXCL10: in vitro comparison with current asthma therapies

Figure 3

The effects of budesonide and formoterol on asthmatic (A) and non-asthmatic (NA) ASMC CXCL10 release induced by cytomix. Confluent serum-deprived ASMC were treated with A) budesonide, B) formoterol or C) both agents for 1 h prior to and during stimulation with cytomix (IL-1β, TNF-α and IFNγ combined, each at 10 ng/ml) and CXCL10 release after 24 h quantified by ELISA. Bars, mean ± SEM.

Back to article page